Oral polio vaccine neurovirulence tests
Executive Summary
Lederle files petition with FDA on June 7 seeking a stay of action on the effective date of the agency's recently published rule on neurovirulence testing standards for oral polio vaccine. On the same day, Lederle also filed objections and request for a hearing on the OPV test standards. FDA's OPV final rule, published May 8, was essentially a compromise measure that permitted use of both WHO test standards, sought by Connaught, and the U.S. standard used by Lederle for the past 25 years ("The Pink Sheet" May 20, T&G-6). Lederle maintains that "any change in safety testing for [OPV] must be justified by a conclusive demonstration that the new test is at least as good as the old".
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth